China FDA to issue catalogue of all drugs marketed in China

A Chinese Version of the USFDA’s “Orange Book” will be available soon

The China Food and Drug Administration (CFDA)’s Center for Drug Evaluation (CDE) issued draft rules that will underpin the development of a catalog of all drugs listed on the China market – in other words, a Chinese version of the U.S. FDA’s Orange Book. The CDE is solicited public feedback until September 15, 2017.

Copyright Widler & Schiemann AG 2015. All Rights Reserved. /